Paxton Secures $720M from Drug Manufacturers for their Role in the Catastrophic Opioid Epidemic

Translate to Spanish or other 102 languages!

Attorney General Ken Paxton secured a new opioid settlement worth $720 million with eight drug makers that manufactured opioid pills and worsened the nationwide opioid crisis. In partnership with State Attorneys General across the country, this settlement will allow all local governments to participate through a sign-on period. The State of Texas and its political subdivisions could receive up to $45.5 million. Image for illustration purposes
Attorney General Ken Paxton secured a new opioid settlement worth $720 million with eight drug makers that manufactured opioid pills and worsened the nationwide opioid crisis. In partnership with State Attorneys General across the country, this settlement will allow all local governments to participate through a sign-on period. The State of Texas and its political subdivisions could receive up to $45.5 million. Image for illustration purposes
- Advertisement -

AUSTIN – Attorney General Ken Paxton secured a new opioid settlement worth $720 million with eight drug makers that manufactured opioid pills and worsened the nationwide opioid crisis. In partnership with State Attorneys General across the country, this settlement will allow all local governments to participate through a sign-on period. The State of Texas and its political subdivisions could receive up to $45.5 million. 

“These manufacturers played a role in creating one of the most destructive public health crises our country has ever faced,” said Attorney General Paxton. “These settlements are an important step in holding companies accountable for their reckless greed and the part they had in worsening the opioid epidemic, which has devastated our communities and poisoned countless Texans.” 

The eight defendants and the total amount they will pay in funds to address the opioid crisis as part of the deal are: 

- Advertisement -
  • Mylan (now a part of Viatris): $284,447,916 paid over nine years  
  • Hikma: $95,818,293 paid over one to four years  
  • Amneal: $71,751,010 paid over 10 years  
  • Apotex: $63,682,369 paid in a single year  
  • Indivior: $38,022,450 paid over four years  
  • Sun: $30,992,087 paid over one to four years  
  • Alvogen: $18,680,162 paid in a single year  
  • Zydus: $14,859,220 paid in a single year  

In addition to these abatement payments, the companies have also agreed to injunctive relief. Seven of the companies—not including Indivior—are prohibited from promoting or marketing opioid products, from making or selling any product that contains more than 40 mg of oxycodone per pill, and are required to put in place a monitoring and reporting system for suspicious orders. Indivior, for its part, has agreed to not manufacture or sell opioid products for the next 10 years, but it will be able to continue marketing and selling medications to treat opioid use disorder. 

Including this new settlement, Attorney General Paxton has obtained settlements committing nearly $3.34 billion in funds for Texas from companies that helped fuel the catastrophic opioid crisis.  

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

FDA Authorizes First Wearable Device that Continuously Monitors Both Ketone Levels and Blood Sugar

The U.S. Food and Drug Administration today authorized the Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for people aged 2 years and older living with diabetes.

STHS McAllen Launches Naming Contest for Advanced Surgical Robot

Using advanced robotic technology to assist surgeons in performing complex procedures with enhanced precision, dexterity and control, robotic surgery represents one of the most significant advancements in modern medicine.

DHR Health Raises Over $520K at 20th “Fishing for Hope” Event

DHR Health made a big splash at the 20th Annual “Fishing for Hope” Tournament, held on August 22 at Jim’s Pier in South Padre Island, raising an impressive grand total of $524,130.

FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer

The U.S. Food and Drug Administration approved Rasonque (daraxonrasib), a RAS inhibitor for the most common form of pancreatic cancer—delivering a new treatment option to patients with advanced pancreatic cancer months ahead of schedule. 
- Advertisement -